Revolution Medicines, Inc.
RVMD
Rank in Stocks
#646
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Share Price
$176.71
Last synced: 2026-10-16
Market Cap
$37.88B
Change (1 day)
-6.63%
Change (1 year)
226.64%
Country
US
Trade Revolution Medicines, Inc. (RVMD)
Category
Healthcare
Operating Margin for Revolution Medicines, Inc. (RVMD)
Operating Margin as of October 2026 TTM: 0.00%
According to Revolution Medicines, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2023 the company had an Operating Margin of -4,207.12%.
Operating Margin history for Revolution Medicines, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -4,207.12% | 476.31% |
| 2022 | -730.01% | 14.12% |
| 2021 | -639.70% | 148.39% |
| 2020 | -257.54% | 138.13% |
| 2019 | -108.15% | -45.93% |
| 2018 | -200.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.